Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

• Published in: Clinical cancer research 2024-08, Vol.30 (15), p.3200-3210
• Main Authors: Nguyen, Charles B, Reimers, Melissa A, Perera, Chamila, Abida, Wassim, Chou, Jonathan, Feng, Felix Y, Antonarakis, Emmanuel S, McKay, Rana R, Pachynski, Russell K, Zhang, Jingsong, Reichert, Zachery R, Palmbos, Phillip L, Caram, Megan E V, Vaishampayan, Ulka N, Heath, Elisabeth I, Hopkins, Alexander C, Cieslik, Marcin P, Wu, Yi-Mi, Robinson, Dan R, Baladandayuthapani, Veerabhadran, Chinnaiyan, Arul M, Alva, Ajjai S
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor; Cyclin-Dependent Kinases - antagonists & inhibitors; Humans; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Ipilimumab - administration & dosage; Ipilimumab - adverse effects; Ipilimumab - therapeutic use; Male; Middle Aged; Mutation; Neoplasm Metastasis; Nivolumab - administration & dosage; Nivolumab - therapeutic use; Progression-Free Survival; Prostate-Specific Antigen - blood; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Prostatic Neoplasms, Castration-Resistant - pathology
• ISSN: 1078-0432; 1557-3265; 1557-3265
• DOI: 10.1158/1078-0432.CCR-24-0400

CDK12 inactivation in metastatic castration-resistant prostate cancer (mCRPC) may predict immunotherapy responses. This phase 2 trial evaluated the efficacy of immune checkpoint inhibitor (ICI) therapy in patients with CDK12-altered mCRPC. Eligible patients had mCRPC with deleterious CDK12 alterations and any prior therapies except ICI. Cohort A received ipilimumab (1 mg/kg) with nivolumab (3 mg/kg) every 3 weeks for up to four cycles, followed by nivolumab 480 mg every 4 weeks. Cohort C received nivolumab alone 480 mg every 4 weeks. Patients with CDK12-altered nonprostate tumors were enrolled in cohort B and not reported. The primary endpoint was a 50% reduction in PSA (PSA50). Key secondary endpoints included PSA progression-free survival, overall survival, objective response rate, and safety. PSA was evaluable in 23 patients in cohort A and 14 in cohort C. Median lines of prior therapy were two in cohorts A and C, including any prior novel hormonal agent (74% and 79%) and chemotherapy (57% and 36%). The PSA50 rate was 9% [95% confidence interval (CI), 1%-28%] in cohort A with two responders; neither had microsatellite instability or a tumor mutational burden >10 mutations/megabase. No PSA50 responses occurred in cohort C. Median PSA progression-free survival was 7.0 months (95% CI, 3.6-11.4) in cohort A and 4.5 months (95% CI, 3.4-13.8) in cohort C. Median overall survival was 9.0 months (95% CI, 6.2-12.3) in cohort A and 13.8 months (95% CI, 3.6-not reached) in cohort C. There was minimal activity with ICI therapy in patients with CDK12-altered mCRPC.